Jazz Pharmaceuticals JAZZ Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Ionis PharmaceuticalsIONS

$2.73M+58.3%

AmgenAMGN

——

BridgeBio PharmaBBIO

——

BiogenBIIB

——

Neurocrine BiosciencesNBIX

——

ExelixisEXEL

——

Other financials

Income statement

See full

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Balance sheet

See full

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Cash flow

See full

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Valuation

See full

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Profitability

See full

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Returns & leverage

See full

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Jazz Pharmaceuticals's unrealized losses on investments (before tax)?: Jazz Pharmaceuticals (JAZZ) reported unrealized losses on investments (before tax) of $0 in Q1 2026.